Nvidia’s CEO search reportedly approaches Arm chief Rene Haas
Nvidia's board has sounded out Arm boss Rene Haas about replacing Jensen Huang, the FT reported, a day after Huang quit and days before Nvidia's earnings.
Nvidia's board has sounded out Arm boss Rene Haas about replacing Jensen Huang, the FT reported, a day after Huang quit and days before Nvidia's earnings.
Nvidia's co-founder has quit as chief executive and left the board after days of scandal. Shares swung sharply on Thursday as investors weighed life after Huang.
The UK challenger lender has launched a formal sale process with Morgan Stanley advising, though it says no bidder has approached it yet. Its shares rose as much as 6% on Thursday.
London-based Fractile, which designs chips for running AI models, has raised $720mn at a $7bn valuation, a big bet on an Nvidia challenger whose first product is not yet on sale.
Hong Kong's exchange has cleared Alibaba to spin off T-Head, the designer of its Zhenwu AI chips, giving investors a possible way to own China's homegrown chip push directly.
A day into its roadshow, the Claude maker's listing is reportedly drawing orders several times the shares on offer, and its banks may push the price above the $70 to $78 range.
CoreWeave's sales jumped 168% to $3.66 billion and it raised its 2026 outlook, lifting the battered stock, while CEO Michael Intrator said he has paused his planned stock sales.
Nigeria's Dangote Cement has put its London share sale on hold after last week's global selloff, a fresh setback for a UK market that is struggling to win big new listings.
Charges on power gear for US data centers and soaring interest bills pushed SoftBank Group into a surprise loss, a fresh test of its costly AI push.
The Claude maker's updated filing puts a price on its long-awaited listing, implying a fully diluted value of about $1.4 trillion, below the $2 trillion once floated.
UniCredit expects its last approvals for Commerzbank by the end of November, as the Italian bank posts record quarterly profit. The bigger fight over who runs the German lender is about to start.
The US regulator wants every GLP-1 drug, including Wegovy and Zepbound, to flag a rare optic nerve condition. The risk looks small, but it touches the industry's biggest sellers.